Background and aim Hepatocellular carcinoma (HCC) is one of the top five leading causes of death in Egypt and its prevalence is increasing in the next 10-20 years. We aimed to detect the serum Golgi protein 73 (GP73) in patients with cirrhosis and with HCC, and to determine its sensitivity and specificity as a screening tool for the detection of HCC in this study. Patients and methods Serum GP73 was estimated in 93 participants (patients with HCC, patients with cirrhosis, and healthy controls). Results GP73 was elevated in patients with HCC and liver cirrhosis; serum level was very high in HCC patients (P < 0.01) when compared with the other studied groups. GP73 had sensitivity of 76%, specificity of 75%, at a cut-off value of 16.2 ng/ml with area under the receiver operator characteristic of 0.825 when compared with a-fetoprotein that showed a sensitivity of 63%, specificity of 43% at a cut-off value of 16.5 ng/ml and area under the receiver operator characteristic of 0.611. By combining a-fetoprotein and GP73 for the diagnosis of HCC, sensitivity and specificity were (93 and 25%), respectively. There is a significant positive correlation between diameter of the focal lesion and GP73 (P = 0.01 and r = 0.071). Nonsignificant positive correlation was detected as regards serum GP73 and the number of HCC. Conclusion GP73 can be used as a screening tool for the detection of HCC. Moreover, it shows a higher serum level with larger lesions.Receiver operating characteristic curve for GP73 and a-fetoprotein in the hepatocellular carcinoma group. Figure 3Correlation between GP73 and the size of hepatocellular carcinoma; HLF, hepatic focal lesion.Using GP73 for the detection of HCC Omran et al. 45
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.